{"title":"Characteristics associated with first anti-seizure medication prescribed in a cohort of adults with newly diagnosed epilepsy","authors":"Leah J. Blank , Rachelle Morgenstern , Kenneth Boockvar , Nihal Mohamed , Nathalie Jetté","doi":"10.1016/j.seizure.2026.02.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Anti-seizure medication (ASM) is the primary treatment modality in epilepsy. There exist evidence-based recommendations published by the American Academy of Neurology and American Epilepsy Society for ASM selection in epilepsy, but these medication recommendations are inconsistently followed. We sought to examine predictors of recommended first ASM in newly diagnosed adults with epilepsy.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of adults (≥18 years) newly diagnosed with epilepsy in New York, identified using validated ICD-CM codes, for the period 2011 to 2019. The primary outcome of interest was use of an AES/AAN guideline-informed ASM, and exposures of interest included patient characteristics (e.g. age), provider characteristics (e.g. specialty) and structural characteristics (e.g., practice setting). Multivariable Poisson regression for risk ratios modeled the probability of being prescribed a neutral/recommended or non-recommended ASM, adjusting for covariates.</div></div><div><h3>Results</h3><div>2340 adults with newly diagnosed epilepsy were prescribed an ASM within 1-year. The most frequently prescribed ASM was levetiracetam (45.5%), which aligns with recommendations. However, 39% were prescribed a non-recommended medication. The prescription of a recommended ASM was associated with older age at diagnosis (relative risk (RR) 1.01; 95% confidence interval (CI) 1.00–1.01), Black race (RR 1.12; 95% CI 1.03–1.23), being in a relationship (vs. divorced/separated/single or widowed) (RR 1.13; 95% CI 1.06–1.22) and a history of stroke (RR 1.19; 95% CI 1.05–1.34). Prescriptions from physician trainees (vs. non-trainees) were more likely to align with recommended ASMs (RR 1.15; 95% CI 1.06–1.25), with no differences by physician specialty. Inpatient setting was associated with fewer recommended ASM prescriptions (vs. outpatient setting) (RR 0.82; 95% CI 0.75–0.89). There was no difference between emergency department and outpatient prescriptions.</div></div><div><h3>Conclusions</h3><div>Understanding where/why less favorable ASM prescription may occur is important to target potential prescribing interventions. In this study, recommended ASM prescriptions were associated with patient, prescriber and setting characteristics. Notably, trainees prescribed recommended/neutral ASM more often, which underscores the importance of prescriber education in improving prescribing practices.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"136 ","pages":"Pages 60-65"},"PeriodicalIF":2.8000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seizure-European Journal of Epilepsy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S105913112600035X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Anti-seizure medication (ASM) is the primary treatment modality in epilepsy. There exist evidence-based recommendations published by the American Academy of Neurology and American Epilepsy Society for ASM selection in epilepsy, but these medication recommendations are inconsistently followed. We sought to examine predictors of recommended first ASM in newly diagnosed adults with epilepsy.
Methods
We conducted a retrospective cohort study of adults (≥18 years) newly diagnosed with epilepsy in New York, identified using validated ICD-CM codes, for the period 2011 to 2019. The primary outcome of interest was use of an AES/AAN guideline-informed ASM, and exposures of interest included patient characteristics (e.g. age), provider characteristics (e.g. specialty) and structural characteristics (e.g., practice setting). Multivariable Poisson regression for risk ratios modeled the probability of being prescribed a neutral/recommended or non-recommended ASM, adjusting for covariates.
Results
2340 adults with newly diagnosed epilepsy were prescribed an ASM within 1-year. The most frequently prescribed ASM was levetiracetam (45.5%), which aligns with recommendations. However, 39% were prescribed a non-recommended medication. The prescription of a recommended ASM was associated with older age at diagnosis (relative risk (RR) 1.01; 95% confidence interval (CI) 1.00–1.01), Black race (RR 1.12; 95% CI 1.03–1.23), being in a relationship (vs. divorced/separated/single or widowed) (RR 1.13; 95% CI 1.06–1.22) and a history of stroke (RR 1.19; 95% CI 1.05–1.34). Prescriptions from physician trainees (vs. non-trainees) were more likely to align with recommended ASMs (RR 1.15; 95% CI 1.06–1.25), with no differences by physician specialty. Inpatient setting was associated with fewer recommended ASM prescriptions (vs. outpatient setting) (RR 0.82; 95% CI 0.75–0.89). There was no difference between emergency department and outpatient prescriptions.
Conclusions
Understanding where/why less favorable ASM prescription may occur is important to target potential prescribing interventions. In this study, recommended ASM prescriptions were associated with patient, prescriber and setting characteristics. Notably, trainees prescribed recommended/neutral ASM more often, which underscores the importance of prescriber education in improving prescribing practices.
背景:抗癫痫药物(ASM)是癫痫的主要治疗方式。美国神经病学学会和美国癫痫学会发表了针对癫痫患者ASM选择的循证建议,但这些药物建议并没有得到一致的遵循。我们试图检查新诊断的成人癫痫患者推荐的首次ASM的预测因素。方法:我们对2011年至2019年期间纽约新诊断为癫痫的成人(≥18岁)进行了回顾性队列研究,使用经过验证的ICD-CM代码进行鉴定。关注的主要结果是使用AES/AAN指南告知的ASM,关注的暴露包括患者特征(如年龄)、提供者特征(如专业)和结构特征(如实践环境)。风险比的多变量泊松回归模拟了规定中性/推荐或非推荐ASM的概率,调整了协变量。结果2340例成人新诊断癫痫患者在1年内接受了ASM治疗。最常见的ASM处方是左乙拉西坦(45.5%),这与建议一致。然而,39%的人服用了非推荐药物。推荐的ASM处方与诊断时年龄较大相关(相对风险(RR) 1.01;95%可信区间(CI) 1.00-1.01)、黑人(RR 1.12; 95% CI 1.03-1.23)、恋爱(相对于离婚/分居/单身或丧偶)(RR 1.13; 95% CI 1.06-1.22)和中风史(RR 1.19; 95% CI 1.05-1.34)。实习医师开具的处方(与非实习医师相比)更有可能与推荐的asm一致(RR 1.15; 95% CI 1.06-1.25),不同医师专业之间没有差异。住院环境与较少推荐的ASM处方相关(与门诊环境相比)(RR 0.82; 95% CI 0.75-0.89)。急诊和门诊处方之间没有差异。结论了解不良ASM处方可能发生的地点/原因对于针对潜在的处方干预措施非常重要。在本研究中,推荐的ASM处方与患者、处方者和环境特征相关。值得注意的是,受训者开推荐/中性ASM的频率更高,这强调了开处方者教育在改善开处方实践中的重要性。
期刊介绍:
Seizure - European Journal of Epilepsy is an international journal owned by Epilepsy Action (the largest member led epilepsy organisation in the UK). It provides a forum for papers on all topics related to epilepsy and seizure disorders.